Mabwell's LILRB4/CD3 Bispecific Antibody 6MW5311 Receives NMPA IND Approval for Leukemia Treatment

Key Takeaways

• NMPA accepts IND application for Mabwell’s first-in-class LILRB4/CD3 bispecific antibody targeting blood cancers
• 6MW5311 will enter clinical trials for Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
• This regulatory milestone positions Mabwell to advance novel immunotherapy approach for hard-to-treat hematologic malignancies

---

Mabwell Advances Blood Cancer Treatment with Regulatory Approval

Shanghai-based biopharmaceutical company Mabwell (688062.SH) announced on April 16, 2026, that China’s National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for its innovative LILRB4/CD3 T-cell engager (TCE) bispecific antibody, designated 6MW5311.

Novel Mechanism Targets Blood Cancers

The 6MW5311 bispecific antibody represents a cutting-edge approach to treating hematologic malignancies by simultaneously targeting LILRB4 (Leukocyte Immunoglobulin-like Receptor B4) and CD3. This dual-targeting mechanism is designed to redirect T-cells to attack cancer cells expressing LILRB4, which is commonly found on certain blood cancer cells.

The drug candidate will initially focus on treating Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML), two aggressive blood cancers with significant unmet medical needs. AML affects approximately 20,000 new patients annually in the United States, with five-year survival rates remaining below 30% for most age groups.

Market Impact and Clinical Significance

This IND acceptance marks a significant milestone for Mabwell’s oncology pipeline and represents the growing trend toward bispecific antibodies in cancer treatment. The LILRB4 target is particularly promising because it’s highly expressed on leukemic stem cells, which are often responsible for treatment resistance and disease relapse.

The approval enables Mabwell to initiate Phase I clinical trials, where researchers will evaluate the safety, tolerability, and preliminary efficacy of 6MW5311 in patients with relapsed or refractory hematologic malignancies.

Industry Context

Bispecific antibodies have emerged as a promising cancer treatment modality, with several approved therapies demonstrating significant clinical benefits. Mabwell’s entry into this space with a novel target combination could provide new treatment options for patients who have exhausted standard therapies.

The company’s integrated biopharmaceutical platform positions it well to advance 6MW5311 through clinical development, potentially addressing critical gaps in blood cancer treatment.

---

Frequently Asked Questions

What does this NMPA approval mean for patients with blood cancer?

The IND acceptance allows Mabwell to begin clinical trials testing 6MW5311 in patients with AML and CMML. While still experimental, this represents a potential new treatment option for patients with limited alternatives, particularly those with relapsed or treatment-resistant disease.

When will 6MW5311 be available as a treatment option?

6MW5311 is entering Phase I clinical trials and is years away from potential market availability. If successful through all clinical phases and regulatory review, the drug could potentially reach patients in 5-8 years, though this timeline can vary significantly based on trial results.

How does this bispecific antibody differ from current leukemia treatments?

Unlike traditional chemotherapy or single-target therapies, 6MW5311 uses a bispecific design to simultaneously bind cancer cells (via LILRB4) and immune cells (via CD3), essentially turning the patient’s own T-cells into targeted cancer fighters. This approach may offer improved efficacy with potentially fewer side effects than conventional treatments.